Answers are grounded in this paper and cite their sources.
Vitamin D deficiency is highly prevalent in India despite abundant sunlight and may contribute to the broader Indian nutrimetabolic phenotype, characterized by central adiposity, insulin resistance, dyslipidemia, early β -cell dysfunction, and micronutrient insufficiencies. This expert review aimed to define the Indian nutrimetabolic phenotype, examine the contribution of vitamin D deficiency and related micronutrient factors, and provide practical guidance on screening, supplementation, and fortification strategies relevant to Indian clinical practice. A structured literature review was conducted using PubMed and Google Scholar, followed by a two-round Delphi process involving 14 endocrinologists. Evidence summaries and draft statements were rated anonymously, with consensus defined as ≥80% agreement; unresolved areas were refined during an in-person advisory board meeting. Consensus was reached on 22 expert insights organized under seven clinical questions and three thematic domains: phenotypic definition, prevention and risk management, and therapeutic supplementation principles. The panel concluded that the Indian nutrimetabolic phenotype is a modifiable construct shaped by diet, lifestyle, adiposity, metabolic risk, and micronutrient status and that vitamin D deficiency should be identified and corrected as part of comprehensive metabolic care, particularly in individuals with obesity, insulin resistance, type 2 diabetes mellitus/prediabetes, cardiovascular disease, and chronic kidney disease. Supplementation should be individualized according to baseline 25-hydroxyvitamin D levels, deficiency severity, body mass index, comorbidities, and safety considerations, with retesting after 8–12 weeks where appropriate. However, vitamin D should not be positioned as a standalone metabolic therapy or routine disease prevention strategy in vitamin D-sufficient individuals. Further studies in Indian populations are needed to validate population-specific thresholds, optimize dosing, and determine whether correction of deficiency improves clinically meaningful metabolic outcomes.
No takes yet. Share an insight, caveat, or question.
Kalra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: